Abdoul Karim SANGARE

Dr. Abdoul Karim SANGARE

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 November 2020 in Viruses
Verified
Journal Article
Open access
PDF file
BKBourema Kouriba
Bourema Kouriba
ADAngela Dürr
Angela Dürr
ARAlexandra Rehn
Alexandra Rehn
ASAbdoul Karim SANGARE
Abdoul Karim SANGARE
Bréhima TraoréBréhima Traoré
Bréhima Traoré
MAMarkus Antwerpen
Markus Antwerpen
We are currently facing a pandemic of COVID-19, caused by a spillover from an animal-originating coronavirus to humans occurring in the Wuhan region of China in December 2019. From China, the virus has spread to 188 countries and regions worldwide, reaching the Sahel region on 2 March 2020. Since whole genome sequencing (WGS) data is very crucial to understand the spreading dynamics of the ongoing pandemic, but only limited sequencing data is available from the Sahel region to date, we have focused our efforts on generating the first Malian sequencing data available. Screening 217 Malian patient samples for the presence of SARS-CoV-2 resulted in 38 positive isolates, from which 21 whole genome sequences were generated. Our analysis shows that both the early A (19B) and the later observed B (20A/C) clade are present in Mali, indicating multiple and independent introductions of SARS-CoV-2 to the Sahel region.

25 September 2020 in medRxiv
Verified
Preprint
Open access
PDF file
BKBourema Kouriba
Bourema Kouriba
ADA Dürr
A Dürr
ARAlexandra Rehn
Alexandra Rehn
ASAbdoul Karim SANGARE
Abdoul Karim SANGARE
TRTraoré
Traoré
RWRoman Woelfel
Roman Woelfel
We are currently facing a pandemic of COVID-19, caused by a spillover from an animal-originating coronavirus to humans occuring in the Wuhan region, China, in December 2019. From China the virus has spread to 188 countries and regions worldwide, reaching the Sahel region on the 2nd of March 2020. Since whole genome sequencing (WGS) data is very crucial to understand the spreading dynamics of the ongoing pandemic, but only limited sequence data is available from the Sahel region to date, we have focused our efforts on generating the first Malian sequencing data available. Screening of 217 Malian patient samples for the presence of SARS-CoV-2 resulted in 38 positive isolates from which 21 whole genome sequences were generated. Our analysis shows that both, the early A (19B) and the fast evolving B (20A/C) clade, are present in Mali indicating multiple and independent introductions of the SARS-CoV-2 to the Sahel region.

3 April 2026 in Microbes & Immunity
Verified
Journal Article
Open access
PDF file
ACArama Charles
Arama Charles
GCGaba Komi Carlos
Gaba Komi Carlos
ADAntoine Dara
Antoine Dara
ABAboubacar Dit Tietie BISSAN
Aboubacar Dit Tietie BISSAN
STSidibé Tieido
Sidibé Tieido
KBKouriba Bourema
Kouriba Bourema
Coronavirus disease 2019 (COVID-19) has been associated with the production of autoantibodies and the development of autoimmune disease. However, the prevalence of autoantibodies during the early wave of the pandemic is not known in Mali. We sought to assess the seroprevalence of autoantibodies in patients infected with SARS-CoV-2 during the first wave of COVID-19 in Mali. A retrospective cross-sectional study was conducted from April to July 2020 at the Charles Mérieux Centre of Infectiology, Bamako. We screened 1,271 individuals suspected of having COVID-19. Samples were tested for SARS-CoV-2 antibodies. Overall, 19% of screened individuals were seropositive for anti–SARS-CoV-2 immunoglobulin G and/or M. Subsequently, ninety serum specimens were selected and analyzed for the detection of autoantibodies using an IDS-iSYS chemiluminescence immunoassay. We found a seroprevalence of 32.22% for autoantibodies. Seroprevalence was similar in women (18.89%) and men (13.33%, p = 0.25). The largest age group in this autoantibody seroprevalence study was 41–60 years (44%). Seroprevalence was higher for antinuclear antibodies and anti-beta-2 glycoprotein IgG, at 20% each. However, it was lower for anti-beta-2 glycoprotein I IgM, anti-cardiolipin IgG, and anti-cardiolipin IgM, and anti-myeloperoxidase antibodies, at 7%. The high seroprevalence of autoantibodies could contribute to the onset or the reactivation of autoimmune disorders during coronavirus infection.